NASDAQ:ELOX

Eloxx Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy ELOX

*Your capital is at risk

$0.370

+0 (+0%)

At Close: Jun 03, 2026

Eloxx Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 44.75. In total, the insiders bought 59.07M and sold 1.42M ELOX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	44.75
● Buy	59.07M shares
● Sell	1.42M shares
95% Buy Activity Moderate Positive Correlation
Sell Signal Low Confidence May 27, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 44.75. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 27, 2026 Buy	Common Stock J-Other	Kjellson Nina S Insider	Other	0 Value: $0
May 27, 2026 Buy	Common Stock J-Other	Webster Stephen W Insider	Other	0 Value: $0
May 27, 2026 Sell	Common Stock J-Other	Coastlands Capital Lp 10 Percent Owner	10% Owner	1 250 000 Value: $0
May 27, 2026 Buy	Pre-funded Warrant J-Other	Coastlands Capital Lp 10 Percent Owner	10% Owner	1 250 000 Value: $12.5K
Apr 28, 2026 Buy	Pre-funded Warrant	Domicilium Real Estate Fund Iii Lp 10 Percent Owner	10% Owner	20 841 782 Value: $208.4K
Apr 28, 2026 Buy	Common Stock, $0.01 par value	Domicilium Real Estate Fund Iii Lp 10 Percent Owner	10% Owner	0 Value: $0
Apr 28, 2026 Buy	Common Stock, $0.01 par value	Domicilium Real Estate Fund Iii Lp 10 Percent Owner	10% Owner	0 Value: $0
Apr 27, 2026 Buy	Common Stock	Coastlands Capital Lp 10 Percent Owner	10% Owner	0 Value: $0
Apr 27, 2026 Buy	Pre-funded Warrant	Coastlands Capital Lp 10 Percent Owner	10% Owner	29 362 243 Value: $293.6K
Feb 28, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Aggarwal Sumit President And CEO	CEO / President	260 946 Value: $39.1K
Feb 28, 2026 Buy	Common Stock M-Exempt	Aggarwal Sumit President And CEO	CEO / President	260 946 Value: $39.1K
Jan 24, 2026 Buy	Common Stock M-Exempt	Walts Alan Edmund Director	Director	1 875 Value: $694
Jan 24, 2026 Buy	Restricted Stock Units M-Exempt	Aggarwal Sumit President And CEO	CEO / President	15 000 Value: $6K
Jan 24, 2026 Buy	Common Stock M-Exempt	Aggarwal Sumit President And CEO	CEO / President	15 000 Value: $6K
Jan 24, 2026 Buy	Common Stock M-Exempt	Rubin Steven D Director	Director	1 875 Value: $694
Jan 24, 2026 Buy	Restricted Stock Units M-Exempt	Rubin Steven D Director	Director	1 875 Value: $694
Jan 24, 2026 Buy	Restricted Stock Units M-Exempt	Walts Alan Edmund Director	Director	1 875 Value: $694
Sep 19, 2025 Buy	Common Stock A-Award	Aggarwal Sumit President And CEO	CEO / President	1 000 000 Value: $1K
Sep 19, 2025 Buy	Stock Option (Right to Buy) A-Award	Rubin Steven D Director	Director	179 854 Value: $27.0K
Sep 19, 2025 Buy	Stock Option (Right to Buy) A-Award	Aggarwal Sumit President And CEO	CEO / President	3 597 090 Value: $539.6K
Sep 19, 2025 Buy	Stock Option (Right to Buy) A-Award	Walts Alan Edmund Director	Director	395 680 Value: $59.4K
Aug 14, 2025 Buy	Common Stock M-Exempt	Aggarwal Sumit President And CEO	CEO / President	196 880 Value: $20
Aug 14, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Aggarwal Sumit President And CEO	CEO / President	42 790 Value: $4
Jan 24, 2025 Buy	Common Stock M-Exempt	Aggarwal Sumit Director	Director	30 000 Value: $33
Jan 24, 2025 Buy	Restricted Stock Units M-Exempt	Aggarwal Sumit Director	Director	30 000 Value: $33

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ELOXX PHARMACEUTICALS INC.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for t...

Read Full Profile Here